Skip to main content
SpringerLink
Log in

PORTEC-3-Studie für Endometriumkarzinome mit hohem Risiko: Auswirkungen der molekularen Klassifizierung auf die Prognose und den Nutzen einer adjuvanten Therapie

The PORTEC-3 trial for high-risk endometrial cancer: impact of molecular classification on prognosis and benefit from adjuvant therapy

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB et al (2018) Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 19:295–309

    Article  Google Scholar 

  2. Leon-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, Nijman HW et al (2020) Molecular classification of the PORTEC‑3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 38:3388–3397

    Article  CAS  Google Scholar 

  3. Raffone A, Travaglino A, Mascolo M, Carbone L, Guida M, Insabato L, Zullo F (2019) TCGA molecular groups of endometrial cancer: pooled data about prognosis. Gynecol Oncol 155:374–383

    Article  CAS  Google Scholar 

  4. Marnitz S, Waltar T, Köhler C, Mustea A, Schömig-Markiefka B (2020) The brave new world of endometrial cancer: future implications for adjuvant treatment decisions. Strahlenther Onkol 196:963–972

    Article  CAS  Google Scholar 

  5. Marnitz S, Walter T, Schömig-Markiefka B, Engler T, Kommoss S, Brucker SY (2020) A modern approach to endometrial carcinoma: Will molecular classification improve precision medicine in the future? Cancers (Basel) 12(9):2577

    Article  CAS  Google Scholar 

  6. Creutzberg CL, Nout RA, Lybeert ML, Warlam-Rodenhuis CC, Jobsen JJ, Mens JW, Lutgens LC et al (2011) Fifteen-year radiotherapy outcomes of the randomized PORTEC‑1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 81:e631–e638

    Article  Google Scholar 

  7. Ko E, Funk M, Brewster W (2011) Have PORTEC 1 and GOG 99 changed practice patterns in the United States? Gynecol Oncol 121:S100–S100

    Article  Google Scholar 

  8. Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens L, van der Steen-Banasik EM et al (2018) Ten-year results of the PORTEC‑2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 119:1067–1074

    Article  CAS  Google Scholar 

  9. Randall ME, Filiaci V, McMeekin DS, von Gruenigen V, Huang H, Yashar CM, Mannel RS et al (2019) Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol 37:1810–1818

    Article  CAS  Google Scholar 

  10. Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, Moxley KM et al (2019) Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med 380:2317–2326

    Article  CAS  Google Scholar 

  11. Marnitz S, Köhler C, Gharbi N, Kunze S, Jablonska K, Herter J (2018) Evolution of adjuvant treatment in endometrial cancer-no evidence and new questions? Strahlenther Onkol 194(11):965–974

    Article  CAS  Google Scholar 

  12. Waltar T, Marnitz S (2020) Clinical implications of the PORTEC‑3 trial for the treatment of high-risk endometrial cancer. Strahlenther Onkol 196:410–413

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Radioonkologie, CyberKnife und Strahlentherapie, Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland

    Simone Marnitz

  2. Centrum für Integrierte Onkologie, Köln/Bonn, Deutschland

    Simone Marnitz &  Birgid Schömig-Markiefka

  3. Institut für Pathologie, Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland

    Birgid Schömig-Markiefka

Authors
  1. Simone Marnitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Birgid Schömig-Markiefka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simone Marnitz.

Ethics declarations

Interessenkonflikt

S. Marnitz und B. Schömig-Markiefka geben an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Leon-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, Nijman HW, Singh N, Pollock PM, Bessette P et al (2020) Molecular classification of the PORTEC‑3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 38(29):3388–3397

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marnitz, S., Schömig-Markiefka, B. PORTEC-3-Studie für Endometriumkarzinome mit hohem Risiko: Auswirkungen der molekularen Klassifizierung auf die Prognose und den Nutzen einer adjuvanten Therapie. Strahlenther Onkol 197, 266–268 (2021). https://doi.org/10.1007/s00066-020-01735-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-020-01735-4

Search

Navigation